IKIoannis Karakikes

Ioannis Karakikes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ioannis Karakikes has a total of 359 co-authors. Here are the top co-authors by number of shared publications:

  • Mohamed Ameen

    Department of Cancer Biology, Stanford University, Stanford, USA

    10 shared publications
  • Nike Bharucha

    Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA

    8 shared publications
  • Joseph C. Wu

    Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, USA

    7 shared publications
  • Nirmal Vadgama

    Department of Cardiothoracic Surgery and Cardiovascular Institute, Stanford University, Palo Alto, USA

    7 shared publications
  • Jamal Nasir

    Division of Life Sciences, University of Northampton, Northampton, UK

    6 shared publications
  • Jennifer Arthur Ataam

    Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, USA; Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA

    6 shared publications

Latest Publications

  • Open Access

    Shared and Divergent Features of Cardiac Transcriptome and Glucose Metabolism Markers in Human and Mouse HFpEF

    by Kajol Thapa, Kleio-Maria Verrou, Erjola Rapushi, Georgios Siokatas, Karthickeyan Chella Krishnan, Nike Bharucha, Brendan J Keating, Markus Meyer, Ioannis Karakikes, Konstantinos Drosatos

    Heart Failure with Preserved Ejection Fraction (HFpEF) is more prevalent in females and is associated with altered cardiac glucose metabolism. However, whether these metabolic alterations are conserved across sexes and between humans and widely used cardiometabolic mouse model of HFpEF remains unclear. We investigated species-, sex-, and ventricle-specific conserved and divergent features of HFpEF. Cardiometabolic HFpEF was induced in mice using the “two-hit” model (high-fat diet + L-NAME), followed by assessment of cardiac function, RNA sequencing, and protein expression in the right (RV) and left (LV) ventricles. Published human HFpEF RV and LV RNA-seq datasets were reanalyzed and compared with our mouse data. Only male HFpEF mice recapitulated human phenotype of increased RV GLUT1 protein. In contrast, mouse GLUT1 was downregulated in RV of females and in the LV of both sexes, whereas GLUT4 protein remained unchanged. Cardiac PDK4 transcript and protein levels increased in the RV and LV of mice. Conversely, human PDK4 mRNA levels were reduced in the RV with HFpEF and unchanged in LV. Cardiac transcriptome analysis in mice revealed extensive alterations in LV, particularly in females, with enrichment of inflammatory pathways. Cross-species analysis demonstrated greater conservation of HFpEF-associated signatures in the RV than the LV. Furthermore, number of differentially expressed transcripts in human LV increased substantially after excluding patients with atrial fibrillation or diabetes. Overall, the RV of the “two-hit” model more closely resembles human HFpEF. The cardiac transcriptome reflects sexual dimorphism, and conserved signatures are primarily associated with metabolic alteration, mitochondrial dysfunction, and cellular stress. HIGHLIGHTS: The human RV GLUT1 phenotype is reproduced in male mice with HFpEF. HFpEF-related cardiac transcriptome changes are more pronounced in female mice. RV shows greater cross-species conservation than LV in HFpEF. Conserved transcriptomic changes primarily reflect alterations in metabolism and cellular stress. Humans and mice with HFpEF have opposite PDK4 expression profiles. GRAPHICAL

  • Open Access

    The MIRO1-BAX Complex Dictates Life and Death at the Mitochondrial Gate

    by Alva G. Sainz, Chulhwan S. Kwak, Kwang Bog Cho, Sejal A. Sripadanna, Brandon H. Bergsneider, Zoe Zizzo, Aarooran S. Durairaj, Zehui Du, Ian Cooney, Anthony Venida, et al.

    BAX macropores in the outer mitochondrial membrane (OMM) are canonical mediators of apoptosis, but whether the same pore structure can drive distinct cell death pathways remains unclear. Here, we identify the OMM protein MIRO1 as a context-specific modulator of BAX activity. Mechanistically, MIRO1 binds BAX via MIRO1’s N-terminal domain to promote macropore formation and the release of mitochondrial DNA (mtDNA) into the cytoplasm, triggering the STING-pIRF3 signaling axis. In glioma cells, this pathway sustains GPX4 expression via pIRF3-mediated transcriptional activation and confers ferroptosis resistance while bypassing inflammation. By contrast, in Parkinsonian neurons, the MIRO1-BAX complex promotes mitochondrial-stress-induced apoptosis. Using structure-guided drug discovery, we developed first-in-class small molecules that allosterically disrupt the MIRO1-BAX complex by engaging MIRO1’s distal GTPase pocket. These compounds sensitize glioma cells to ferroptosis and protect neurons from apoptosis. Our findings reveal a disease-specific mitochondrial switch for life-death decisions and illuminate the molecular logic by which cells exploit and interpret OMM permeabilization.

  • Connexin-43 Restoration Alleviates Desmosomal Arrhythmogenic Cardiomyopathy

    by Jing Zhang, Fabian Zanella, Matthew W. Ellis, William H. Bradford, Erika Joana Gutierrez-Lara, Tsui-Min Wang, Kyohei Fujita, Charlize Duron, Ioannis Karakikes, Robert C. Lyon, et al.

    BACKGROUND: Arrhythmogenic cardiomyopathy (ACM) is a fatal genetic heart disease primarily caused by mutations in desmosomal genes, leading to impaired cell-cell adhesion, ventricular arrhythmias, and progressive heart failure. Although gene therapy for specific ACM populations shows promise, it remains unclear whether mutation-agnostic pathways dysregulated across desmosomal mutations could be exploited for therapeutic intervention in this genetically broad and severe population. The reduction in expression of the ventricular gap junction protein Cx43 (connexin-43) is a common molecular alteration underlying desmosomal junctional deficits and arrhythmias, suggesting a potential common underlying mechanism and a therapeutic target for ACM. We hypothesized that restoration of Cx43 expression could be a mutation-agnostic intervention for ACM. METHODS: We exploited adeno-associated-viral-mediated gene therapy to restore the gap junction protein, Cx43, in genetic mouse models and human stem cell models of ACM, harboring loss or mutations in desmosomal genes, including Dsp (desmoplakin), PKP2 (plakophilin-2), and DSG2 (desmoglein-2). RESULTS: Administration of AAV-Cx43 (adeno-associated-viral-mediated connexin-43) gene therapy alleviated the severe biventricular dilatation, contractile dysfunction, and arrhythmias, while prolonging lifespan in 2 severe desmosomal ACM mouse models, either harboring Dsp loss and a prevalent human PKP2 mutation. Viral-mediated restoration of Cx43 could also alleviate physiological deficits in ACM human induced pluripotent stem cell-derived cardiomyocytes harboring PKP2 and DSG2 mutations. Mechanistically, Cx43 targets desmosomal protein expression and relocalization to the cell junction to support their mechanical stabilization and coupling. CONCLUSIONS: By using mouse and human models of desmosomal ACM harboring different mutational backgrounds, we show the sufficiency of Cx43 gene therapy and its restoration to modify and alleviate ACM deficits. These data suggest that noncanonical functions of Cx43, including mechanical modulation and reassembly of the desmosome, are a therapeutic target with the potential to treat diverse ACM populations.


  • Open Access

    CRISPR-MiX: A pooled single-stranded donor strategy to enhance HDR efficiency in human iPSCs

    by Rachel Baum, Narasimha Telugu, Arne A.N. Bruyneel, Maryam Kay, Pooja Nair, Isaac Perea-Gil, Vittavat Termglinchan, Nike Bharucha, Edina Lee, Mark Mercola, et al.


  • Open Access

    Correction: De novo and inherited variants in coding and regulatory regions in genetic cardiomyopathies

    by Nirmal Vadgama, Mohamed Ameen, Laksshman Sundaram, Sadhana Gaddam, Casey Gifford, Jamal Nasir, Ioannis Karakikes, Genomics England Research Consortium

  • Open Access

    Carboxypeptidase D deficiency causes hearing loss amenable to treatment

    by Memoona Ramzan, Natalie Ortiz-Vega, Mohammad Faraz Zafeer, Amanda G. Lobato, Tahir Atik, Clemer Abad, Nirmal Vadgama, Duygu Duman, Nazım Bozan, Enise Avcı Durmuşalioǧlu, et al.

    Genetic factors contributing to hearing loss (HL) are heterogeneous, and effective medical treatments remain limited. We identified 3 distinct missense variants in CPD , encoding carboxypeptidase D, in 5 individuals with congenital deafness from 3 unrelated families, affecting the catalytically active CP domain 2 of this protein. Subsequent analysis of a larger cohort from the 100,000 Genomes Project revealed an enrichment of rare protein-altering CPD variants in individuals with HL. We show that CPD localizes to sensory epithelium and nerve cells in the mouse cochlea, and the enzymatic activity of CPD, crucial for nitric oxide (NO) production through arginine processing, is impaired in affected individuals. The levels of arginine, NO, and cGMP in patient-derived fibroblasts are also decreased, leading to endoplasmic reticulum stress–mediated responses being triggered in the cells. Silencing of Cpd in organotypic mouse cochlea cultures leads to increased apoptosis. Finally, Drosophila models of CPD deficiency display defective Johnston’s organ, impaired auditory transduction, and sensory and movement abnormalities. Notably, these phenotypes are partially rescued by supplementation with arginine or sildenafil, a cGMP enhancer. Our findings establish CPD mutations as a cause of congenital HL, highlighting that the NO signaling pathway offers a promising therapeutic avenue.


  • Enhancing cardiac serine biosynthesis mitigates the progression of dilated cardiomyopathy in mice

    by Maryam Kay, Anne-Maj Samuelsson, Nike Bharucha, Xueyi Li, Rohin Ramchandani, Rachel E. Baum, Diego Ruiz Arvizo, Aurélie Laguerre, Sherin Lajevardi, Shrikaar Kambhampati, et al.


  • Open Access

    Generation of human induced pluripotent stem cell lines from patients with PHACE syndrome

    by Rohin Ramchandani, Chanatjit Cheawsamoot, Giovanni A. Torres, Jennifer Arthur Ataam, Dawn Siegel, Ioannis Karakikes

  • Top Cited Papers

    Gastruloids enable modeling of the earliest stages of human cardiac and hepatic vascularization

    by Oscar J. Abilez, Huaxiao Yang, Yuan Guan, Mengcheng Shen, Zehra Yildirim, Yan Zhuge, Ravichandra Venkateshappa, Shane R. Zhao, Angello H. Gomez, Marcel El-Mokahal, et al.

    Although model organisms have provided insight into the earliest stages of cardiac and hepatic vascularization, we know very little about this process in humans because of ethical restrictions and the technical difficulty of obtaining embryos during very early development. In this study, we demonstrate that micropatterned human pluripotent stem cell–derived gastruloids enable in vitro modeling of the earliest stages of vascularization. We identify a combination of vascular-inducing factors that give rise to cardiac vascularized organoids with a spatially organized and branched vascular network. To show the broader utility of our vascularization strategy, we use the same vascular-inducing factors to produce hepatic vascularized organoids. Our results suggest that a conserved developmental program generates the vasculature within different types of organs.